NIR/MRI‐Guided Oxygen‐Independent Carrier‐Free Anti‐Tumor Nano‐Theranostics

Abstract Imaging‐guided photothermal therapy (PTT)/photodynamic therapy (PDT) for cancer treatment are beneficial for precise localization of the malignant lesions and combination of multiple cell killing mechanisms in eradicating stubborn thermal‐resistant cancer cells. However, overcoming the adverse impact of tumor hypoxia on PDT efficacy remains a challenge. Here, carrier‐free nano‐theranostic agents are developed (AIBME@IR780‐APM NPs) for magnetic resonance imaging (MRI)‐guided synergistic PTT/thermodynamic therapy (TDT). Two IR780 derivatives are synthesized as the subject of nanomedicine to confer the advantages for the nanomedicine, which are by feat of amphiphilic IR780‐PEG to enhance the sterical stability and reduce the risk from reticuloendothelial system uptake, and IR780‐ATU to chelate Mn 2+ for T 1 ‐weighted MRI. Dimethyl 2,2′‐azobis(2‐methylpropionate) (AIBME), acting as thermally decomposable radical initiators, are further introduced into nanosystems with the purpose of generating highly cytotoxic alkyl radicals upon PTT launched by IR780 under 808 nm laser irradiation. Therefore, the sequentially generated heat and alkyl radicals synergistically induce cell death via synergistic PTT/TDT, ignoring tumor hypoxia. Moreover, these carrier‐free nano‐theranostic agents present satisfactory biocompatibility, which could be employed as a powerful weapon to hit hypoxic tumors via MRI‐guided oxygen‐independent PTT and photonic TDT.